

## SUPPLEMENTAL MATERIAL

### **Phase 1 Study of Pembrolizumab Plus Chemotherapy in Japanese Patients With Extensive-Stage Small-Cell Lung Cancer**

Naoyuki Nogami,<sup>1</sup> Takaaki Tokito,<sup>2</sup> Yoshitaka Zenke,<sup>3</sup> Miyako Satouchi,<sup>4</sup> Takashi Seto,<sup>5</sup> Hideo Saka,<sup>6</sup> Junko Otani,<sup>7</sup> Shirong Han,<sup>7</sup> Kazuo Noguchi,<sup>7</sup> Makoto Nishio<sup>8</sup>

<sup>1</sup>Ehime University Graduate School of Medicine, Department of Community Medicine, Pulmonology and Cardiology, Toon, Japan; <sup>2</sup>Division of Respiriology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan; <sup>3</sup>Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan; <sup>4</sup>Department of Thoracic Oncology, Hyogo Cancer Center, Akashi, Japan; <sup>5</sup>Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; <sup>6</sup>Department of Respiratory Medicine, National Hospital Organization Nagoya Medical Center, Nagoya, Japan; <sup>7</sup>MSD K.K., Tokyo, Japan; <sup>8</sup>Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

Corresponding Author: Naoyuki Nogami  
Department of Community Medicine, Pulmonology and  
Cardiology  
Ehime University Graduate School of Medicine  
454 Shitsukawa, Toon, Ehime 791-0295  
Japan  
[Email: nogami.naoyuki.zx@ehime-u.ac.jp](mailto:nogami.naoyuki.zx@ehime-u.ac.jp)

**Table S1. Subsequent anticancer therapy**

| <b>Subsequent therapy</b>                | <b>Second line<br/>(n = 13)</b> | <b>Third line<br/>(n = 8)</b> | <b>Fourth line<br/>(n = 5)</b> |
|--|---------------------------------|-------------------------------|--------------------------------|
| Amrubicin                                | 10                              | 3                             | 0                              |
| Cisplatin plus etoposide                 | 1                               | 0                             | 0                              |
| Carboplatin plus etoposide               | 1                               | 0                             | 0                              |
| Investigational drug                     | 1                               | 1                             | 0                              |
| Topotecan                                | 0                               | 2                             | 0                              |
| Cisplatin plus irinotecan                | 0                               | 2                             | 0                              |
| Eribulin                                 | 0                               | 0                             | 2                              |
| Carboplatin plus paclitaxel              | 0                               | 0                             | 1                              |
| Erlotinib                                | 0                               | 0                             | 1                              |
| Atezolizumab, carboplatin, and etoposide | 0                               | 0                             | 1                              |